06/17/2026
The FDA is drawing a harder line on compounded weight loss drug marketing.
In the May–June 2026 issue of Dispense Times, this article breaks down key violations cited in recent FDA enforcement activity involving compounded GLP-1 marketing and telemedicine platforms.
The article highlights several major areas of concern:
Misleading “generic” terminology
False or implied FDA approval claims
Marketing unapproved new drugs
Unsubstantiated “clinically proven” claims
Use of prohibited or unsupported substances like retatrutide
Risky comparisons to FDA-approved brand-name medications
For pharmacies, compounders, telehealth platforms, marketers, and compliance teams, the message is clear: words matter.
Calling a compounded product “generic,” implying it is FDA-approved, or making clinical claims without proper support can create serious regulatory exposure.
This is a timely read for anyone involved in compounded weight loss medications, patient communications, advertising, or pharmacy compliance.
Read the full article in the May–June 2026 issue of Dispense Times:
https://dispensetimes.com/magazine/dispense-times-magazine-may-june-2026-issue/